Concord Biotech Q3 FY25 Results
Concord Biotech has released its financial results for the Q3 quarter of Financial Year 24-2025. Here's a comprehensive breakdown of the company's performance:
Revenue Analysis
- Current Quarter Revenue: Rs. 244.22 Cr
- Quarter-on-Quarter (QoQ) Change: -21.27% (Previous Quarter: Rs. 310.18 Cr )
- Year-on-Year (YoY) Change: 1.42% (Same Quarter Last Year: Rs. 240.80 Cr )
Profitability Metrics
- Net Profit: Rs. 75.92 Cr
- QoQ Profit Change: -20.70% (Previous Quarter: Rs. 95.74 Cr )
- YoY Profit Change: -2.13% (Same Quarter Last Year: Rs. 77.57 Cr )
Shareholder Returns
- Earnings Per Share (EPS): Rs. 7.26
- QoQ EPS Change: -20.66% (Previous Quarter: Rs. 9.15)
- YoY EPS Change: -2.02% (Same Quarter Last Year: Rs. 7.41)
Performance Summary
Mixed
Concord Biotech had a complex financial situation. Different parts of the business are performing differently, showing a changing market.
This analysis provides a snapshot of Concord Biotech's financial performance. Investors and analysts should consider these results in the context of broader market trends and the company's long-term strategy.
Disclaimer:
This information is for informational purposes only. Please reverify all details from official sources before making any financial decisions. The accuracy and completeness of this data cannot be guaranteed.